TY - JOUR
T1 - Neurologic and cognitive outcomes in sickle cell disease from infancy through adolescence
AU - Mayer, Sarah L.
AU - Fields, Melanie E.
AU - Hulbert, Monica L.
N1 - Funding Information:
AUTHOR DISCLOSURES Dr Fields has equity ownership in Proclara Biosciences and is a consultant for Global Blood Therapeutics. Dr Hulbert has conducted research funded by Global Blood Therapeutics and Forma Therapeutics, is a consultant for Bluebird Bio and Forma Therapeutics, and has a spouse employed at Pfizer Inc. Dr Mayer has disclosed no financial relationships relevant to this article. This commentary does not contain a discussion of an unapproved/ investigative use of a commercial product/device.
Publisher Copyright:
© 2021 by the American Academy of Pediatrics. All rights reserved.
PY - 2021/8
Y1 - 2021/8
N2 - Children with sickle cell disease (SCD) are at risk for neurologic and cognitive complications beginning in early childhood. Current treatment for SCD focuses on primary prevention of complications, such as hydroxyurea for prevention of pain and acute chest syndrome, and chronic transfusion therapy for children who are at high risk for strokes. In this article, the prevalence, pathophysiology, and available interventions to prevent and treat neurologic and cognitive complications of SCD will be reviewed.
AB - Children with sickle cell disease (SCD) are at risk for neurologic and cognitive complications beginning in early childhood. Current treatment for SCD focuses on primary prevention of complications, such as hydroxyurea for prevention of pain and acute chest syndrome, and chronic transfusion therapy for children who are at high risk for strokes. In this article, the prevalence, pathophysiology, and available interventions to prevent and treat neurologic and cognitive complications of SCD will be reviewed.
UR - http://www.scopus.com/inward/record.url?scp=85112576175&partnerID=8YFLogxK
U2 - 10.1542/neo.22-8-e531
DO - 10.1542/neo.22-8-e531
M3 - Article
C2 - 34341160
AN - SCOPUS:85112576175
SN - 1526-9906
VL - 22
SP - e531-e539
JO - NeoReviews
JF - NeoReviews
IS - 8
ER -